Clovis Oncology (XTRA:C6O) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

C6O Stoklara Genel Bakış

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Daha fazla detay

C6O temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Gelirin yılda 48.64% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 5.6% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( €14M )

+ 1 daha fazla risk

Clovis Oncology, Inc. Rakipler

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Paion

XTRA:PA8

€2.6m

Epigenomics

XTRA:ECX

€616.0k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clovis Oncology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.091
52 Haftanın En Yüksek Seviyesi	US$3.00
52 Haftanın En Düşük Seviyesi	US$0.09
Beta	0.95
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-94.05%
33 Yıllık Değişim	-97.84%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.87%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	C6O	DE Biotechs	DE Pazar
7D	0%	0.8%	0.8%
1Y	-94.1%	-18.3%	8.6%

Getiri vs. Endüstri: C6O geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: C6O geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is C6O's price volatile compared to industry and market?
C6O volatility
C6O Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: C6O hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: C6O 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc. Temel Bilgiler Özeti

Clovis Oncology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
C6O temel i̇stati̇sti̇kler
Piyasa değeri	€12.78m
Kazançlar(TTM)	-€233.87m
Gelir(TTM)	€123.50m

0.1x

P/S Oranı

-0.1x

F/K Oranı

C6O aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
C6O gelir tablosu (TTM)
Gelir	US$133.02m
Gelir Maliyeti	US$31.59m
Brüt Kâr	US$101.43m
Diğer Giderler	US$353.33m
Kazançlar	-US$251.91m

Son Raporlanan Kazançlar

Sep 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.74
Brüt Marj	76.25%
Net Kâr Marjı	-189.37%
Borç/Özkaynak Oranı	-158.0%

C6O uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

C6O Stoklara Genel Bakış

Ödüller

Risk Analizi

Clovis Oncology, Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

XTRA:PA8

€2.6m

XTRA:ECX

€616.0k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Clovis Oncology, Inc. Temel Bilgiler Özeti

0.1x

-0.1x

Kazanç ve Gelir